MAPT and Alzheimer disease: A study in transgenic mice has shown that metabolic products of COX-2, like PGF2α, and elevated PGI2 (Wang et al., 2017), induce tau hyperphosphorylation leading to deficits in cognitive function and AD development and progression (Guan and Wang, 2019).